Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880557 | 0.87 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL4881926 | 0.85 | P2RX7 (0.55) | P2RX7MEN1ALDH1A1KMT2AAVPR1A | |
| SCHEMBL4883609 | 0.84 | P2RX7 (0.59) | P2RX7MEN1ALDH1A1KMT2AAVPR1A | |
| SCHEMBL4882840 | 0.82 | P2RX7 (0.56) | P2RX7MEN1ALDH1A1KMT2AAVPR1A | |
| SCHEMBL7568709 | 0.81 | P2RX7 (1.00) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL8381564 | 0.80 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL7572049 | 0.79 | P2RX7 (0.71) | P2RX7MEN1ALDH1A1KMT2AAVPR1A | |
| SCHEMBL4880025 | 0.78 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL4874317 | 0.78 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL4880644 | 0.77 | P2RX7 (0.69) | P2RX7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | claimed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | P2RX7 4/4885MEN1 1244/4885ALDH1A1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.